CDH1 and head and neck cancer: The DNMT1 inhibitor 5‐aza‐CdR decreased the methylation level of cadherin‐1 (CDH1) in head and neck cancer, increasing E‐cadherin expression and decreasing ferroptosis sensitivity (Figure 4A).65